Protein Kinase Inhibitors: all 15,278 studies that test it

Page 49 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT01907815Phase 2Results posted
• Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01907607Phase 2Results posted
• Nintedanib (BIBF 1120) in MesotheliomaTerminatedNCT01907100Phase 2/3Results posted
• Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008CompletedNCT01903733Not applicableResults posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT01900002Phase 2Results posted
• A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT01899053Phase 1Results posted
• Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or LymphomasCompletedNCT01898078Phase 1Results posted
• A Study of Baricitinib and Birth Control Pills in Healthy FemalesCompletedNCT01896726Phase 1Results posted
• A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction CancerCompletedNCT01896531Phase 2Results posted
• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerActive, not recruitingNCT01896479Phase 4Results posted
• Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and TolerabilityCompletedNCT01895946Phase 1Results posted
• BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 MutationCompletedNCT01894672Phase 2Results posted
• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerTerminatedNCT01891357Phase 2Results posted
• Maintenance Dovitinib for Colorectal and Pancreas CancerTerminatedNCT01888965Phase 2Results posted
• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2Results posted
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT01886872Phase 3Results posted
• Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedNCT01885949Phase 2Results posted
• MEK162 for Patients With RAS/RAF/MEK Activated TumorsCompletedNCT01885195Phase 2Results posted
• An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01885078Phase 3Results posted
• Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLCompletedNCT01883362Phase 2Results posted
• A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaCompletedNCT01882803Phase 2Results posted
• Efficacy and Safety of AQX-1125 in IC/BPSCompletedNCT01882543Phase 2Results posted
• Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF InhibitorsCompletedNCT01882439Phase 3Results posted
• A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD KidneysTerminatedNCT01878786Phase 2/3Results posted
• Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator StudyCompletedNCT01877668Phase 3Results posted
• Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungCompletedNCT01877083Phase 2Results posted
• Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaTerminatedNCT01876953Phase 1/2Results posted
• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid CancerCompletedNCT01876784Phase 3Results posted
• Dendritic Cell Vaccines + Dasatinib for Metastatic MelanomaCompletedNCT01876212Phase 2Results posted
• A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorCompletedNCT01874665Phase 2Results posted
• Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast CancerTerminatedNCT01873833Phase 2Results posted
• A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01871805Phase 1/2Results posted
• Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent GlioblastomaTerminatedNCT01870726Phase 1/2Results posted
• Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT01870596Phase 2Results posted
• A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseCompletedNCT01870388Phase 1Results posted
• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive ChemotherapyCompletedNCT01869114Phase 2Results posted
• Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast CancerTerminatedNCT01868503Phase 2Results posted
• Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerCompletedNCT01866410Phase 2Results posted
• Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaCompletedNCT01866293Phase 1/2Results posted
• A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT01865747Phase 3Results posted
• A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryCompletedNCT01864746Phase 3Results posted
• Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib TreatmentCompletedNCT01863745Phase 2Results posted
• Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaTerminatedNCT01861301Phase 2Results posted
• A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy ParticipantsCompletedNCT01859078Phase 1Results posted
• A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01858389Phase 2Results posted
• Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung CancerTerminatedNCT01857271Phase 2Results posted
• LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01856478Phase 3Results posted
• A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01855750Phase 3Results posted
• An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)CompletedNCT01853826Phase 3Results posted
• Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01853644Phase 2Results posted
• Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal ImpairmentCompletedNCT01853046Phase 1Results posted
• Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum TherapyTerminatedNCT01852292Phase 2Results posted
• Non-Myeloablative Conditioning and Bone Marrow TransplantationActive, not recruitingNCT01850108Not applicableResults posted
• Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseCompletedNCT01850004Phase 2Results posted
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
• HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)TerminatedNCT01849588Phase 4Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT01849263Phase 2Results posted
• Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT01848067Phase 1/2Results posted
• Tivozanib for Recurrent GlioblastomaCompletedNCT01846871Phase 2Results posted
• Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT01846624Phase 2Results posted
• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.CompletedNCT01844765Phase 2Results posted
• Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of AlisertibCompletedNCT01844583Phase 1Results posted
• 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedNCT01843348Phase 3Results posted
• Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid CancerTerminatedNCT01843062Phase 3Results posted
• A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue SarcomaTerminatedNCT01842594Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsActive, not recruitingNCT01841736Phase 2Results posted
• Ponatinib for Advanced Medullary Thyroid CancerTerminatedNCT01838642Phase 2Results posted
• Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT01835223Phase 1/2Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryCompletedNCT01835145Phase 2Results posted
• A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral MetastasesCompletedNCT01834651Phase 2Results posted
• BKM120 for Patients With PI3K-activated TumorsCompletedNCT01833169Phase 2Results posted
• A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid TumorsCompletedNCT01832506Phase 1Results posted
• A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node DissectionCompletedNCT01832259Phase 2Results posted
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
• Tofacitinib Ointment For Chronic Plaque PsoriasisCompletedNCT01831466Phase 2Results posted
• Sunitinib in Never-Smokers With Lung AdenocarcinomaCompletedNCT01829217Phase 2Results posted
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedNCT01828112Phase 3Results posted
• LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedNCT01828099Phase 3Results posted
• First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract CarcinomaCompletedNCT01828034Phase 1/2Results posted
• Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder CancerCompletedNCT01827943Phase 2Results posted
• Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular ResponseTerminatedNCT01827930Phase 3Results posted
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
• Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerCompletedNCT01827267Phase 2Results posted
• Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerCompletedNCT01827163Phase 2Results posted
• A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF MelanomaTerminatedNCT01826448Phase 1Results posted
• Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerCompletedNCT01824901Phase 1/2Results posted
• Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of RecurrenceTerminatedNCT01824823Phase 2Results posted
• An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid TumorsTerminatedNCT01822756Phase 1Results posted
• Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency VirusCompletedNCT01822522Phase 1Results posted
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerTerminatedNCT01822496Phase 2Results posted
• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2Results posted
• To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD PatientsCompletedNCT01817855Phase 1Results posted
• Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade GliomaCompletedNCT01817751Phase 2Results posted
• PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT01816984Phase 1/2Results posted
• NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerCompletedNCT01816594Phase 2Results posted
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT01815424Phase 3Results posted

← Protein Kinase Inhibitors overview